Free Trial
→ My public warning after 55 years of watching the markets (From Weiss Ratings) (Ad)tc pixel
NASDAQ:ATRA

Atara Biotherapeutics Q3 2026 Earnings Results & Report

Atara Biotherapeutics logo
$8.10 -0.08 (-0.98%)
As of 04:00 PM Eastern

Atara Biotherapeutics missed analyst earnings expectations but beat on revenue in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.15 versus the -$0.1328 consensus estimate, while revenue of $1.22 million topped the $800 thousand estimate by $424.00 thousand.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Atara Biotherapeutics EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.1328
Beat/Miss
Missed by -$0.0172
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Atara Biotherapeutics Revenue Results

Actual Revenue
$1.22 million
Expected Revenue
$800 thousand
Beat/Miss
Beat by +$424.00 thousand
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Atara Biotherapeutics' Q3 2026 Press ReleasePress Release
(8-K)
Atara Biotherapeutics' Q3 2026 Quarterly reportQuarterly report
(10-Q)

Atara Biotherapeutics Q3 2026 Earnings FAQ

Atara Biotherapeutics (NASDAQ:ATRA) reported earnings of -$0.15 per share for Q3 2026, missing the consensus estimate of -$0.1328. The report was announced on Tuesday, November 10, 2026.

Atara Biotherapeutics reported revenue of $1.22 million for Q3 2026, against a consensus estimate of $800 thousand.

Atara Biotherapeutics Earnings Headlines

Atara Biotherapeutics (ATRA) Expected to Release Quarterly Earnings on Wednesday
November 10 at 2:57 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31189141
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
October 14, 2026  |  marketscreener.comM
Many investors are about to lose everything
Twenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending.tc pixel
November 10 at 1:00 AM  |  Porter & Company (Ad)
Atara Resubmits Tabelecleucel BLA To FDA
September 30, 2026  |  rttnews.comhttps://www.rttnews.com/3695348/atara-resubmits-tabelecleucel-bla-to-fda.aspx
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
September 30, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260930946884/en/atara-biotherapeutics-reports-that-the-tabelecleucel-biologics-license-application-has-been-resubmitted-to-the-u.s.-food-and-drug-administration/
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/atara-biotherapeutics-announces-second-quarter-200500846.html
See More Atara Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atara Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atara Biotherapeutics and other key companies, straight to your email.

About Atara Biotherapeutics

Atara Biotherapeutics (NASDAQ:ATRA) is a biopharmaceutical company focused on developing allogeneic T-cell immunotherapies for cancer and serious diseases associated with Epstein-Barr virus (EBV). The company’s platform uses donor-derived, virus-specific T cells that are designed to recognize and eliminate infected or malignant cells without requiring cells to be collected from each individual patient.

Atara’s lead product, tabelecleucel, is marketed in the European Union under the brand name Ebvallo. The therapy is approved for certain adults and children with EBV-positive post-transplant lymphoproliferative disease, a rare and potentially life-threatening complication that can occur after organ or stem-cell transplantation. Pierre Fabre Laboratories has been responsible for commercialization of Ebvallo in Europe under a strategic partnership with Atara.

Founded in 2012 and headquartered in Thousand Oaks, California, Atara historically pursued additional applications of tabelecleucel and other T-cell therapies, including programs targeting EBV-associated cancers and immune-mediated diseases. Pascal Touchon served as the company’s president and chief executive officer during its development and commercialization efforts. The company’s operations and strategic direction have evolved as it has focused resources on its lead product and regulatory activities in the United States and Europe.

View Atara Biotherapeutics Profile
Earnings Tools